HS014 TFA是一种高效、选择性的黑皮质素MC4受体拮抗剂（Ki=3.16nM）。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
HS014 TFA is a potent and selective melanocortin MC4 receptor antagonist (Ki=3.16nM). HS014 TFA regulates appetite and energy balance by blocking the interaction between the MC4 receptor and endogenous ligands, while also reducing inflammatory responses by inhibiting IL-1β-induced Fos expression[1-2]. HS014 TFA is utilized in research related to obesity, diabetes, and metabolic syndrome[3-4].
In vitro, epidermal melanocytes were pretreated with HS014 TFA (10nM–200nM) for 30 minutes, followed by stimulation with β-MSH (200nM) or the N-terminally modified α-MSH analog NDP-α-MSH (200nM) for 72 hours. HS014 TFA significantly inhibited melanin formation and reduced cAMP production[5]. MC4R-overexpressing M1830 astrocytoma cells were treated with HS014 TFA (1nM) for 12 days. This treatment significantly downregulated the expression of p-JNK, ATF3, and c-Jun proteins, while also suppressing the activation of the JNK signaling pathway[6].
In vivo, HS014 TFA (1μg; 5μl) was administered via a single intracerebroventricular (icv) injection in rats that had been previously induced with fever by lipopolysaccharide (LPS; 30μg/kg; i.p.). HS014 TFA had no significant effect on the febrile response but completely blocked the antipyretic effect produced by the selective MC4R agonist MRLOB-0001 (150ng; icv)[7]. HS014 TFA (3.5ng or 100μg, intranasal infusion) was administered as a single dose 30 minutes before a single prolonged stress (SPS) exposure in rats. The 100μg dose significantly reduced the elevation in plasma corticosterone levels measured 30 minutes after the SPS stressor ended, while both doses prevented the stress-induced short-term increase in corticotropin-releasing hormone (CRH) mRNA levels in the basal medial hypothalamus, as well as the increase in tyrosine hydroxylase (TH) and dopamine-β-hydroxylase (DBH) mRNA levels in the locus coeruleus[8].
References:
[1] Schiöth HB, Mutulis F, Muceniece R, et al. Discovery of novel melanocortin4 receptor selective MSH analogues. Br J Pharmacol. 1998 May;124(1):75-82.
[2] Ercil NE, Galici R, Kesterson RA. HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology (Berl). 2005 Jul;180(2):279-85.
[3] Kask A, Rägo L, Mutulis F, et al. Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats. Biochem Biophys Res Commun. 1998 Apr 7;245(1):90-3.
[4] Gao Z, Lei D, Welch J, et al. Agonist-dependent internalization of the human melanocortin-4 receptors in human embryonic kidney 293 cells. J Pharmacol Exp Ther. 2003 Dec;307(3):870-7.
[5] Spencer JD, Schallreuter KU. Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/melanocortin-4 receptor signaling. Endocrinology. 2009 Mar;150(3):1250-8.
[6] Zhao Y, Xin Y, Chu H. MC4R Is Involved in Neuropathic Pain by Regulating JNK Signaling Pathway After Chronic Constriction Injury. Front Neurosci. 2019 Sep 10;13:919.
[7] Loopuijt LD. Local application of L- threo-hydroxyaspartate and malonate in rats in vivo induces rigidity and damages neurons of the substantia nigra, pars compacta. J Neural Transm (Vienna). 2002 Oct;109(10):1275-94.
[8] Serova LI, Laukova M, Alaluf LG, et al, Blockage of melanocortin-4 receptors by intranasal HS014 attenuates single prolonged stress-triggered changes in several brain regions. J Neurochem. 2014 Dec;131(6):825-35.
HS014 TFA是一种高效、选择性的黑皮质素MC4受体拮抗剂（Ki=3.16nM）。HS014 TFA可通过阻断MC4受体与内源性配体的相互作用来调节食欲和能量平衡，同时通过抑制IL-1β诱导的Fos表达以减少炎症反应[1-2]。HS014 TFA可用于肥胖、糖尿病和代谢综合征的相关研究[3-4]。
在体外，在HS014 TFA（10nM-200nM）预处理表皮黑素细胞30分钟，随后以β-MSH（200nM）或N端修饰的α-MSH类似物NDP-α-MSH（200nM）刺激72小时。HS014 TFA显著抑制了黑色素的形成并降低cAMP生成[5]。HS014 TFA（1nM）处理MC4R过表达的M1830星形胶质细胞12天。HS014 TFA显著下调p-JNK、ATF3及c-Jun的蛋白表达，同时抑制JNK信号通路的活化[6]。
在体内，HS014 TFA（1μg；5µl）通过侧脑室（icv）单次注射，用于处理经脂多糖（LPS；30μg/kg；i.p.）诱导发热的大鼠。HS014 TFA本身对发热反应无显著影响，但可完全阻断选择性MC4R激动剂MRLOB-0001（150ng；icv）所产生的退热效应[7]。HS014 TFA（3.5ng或100μg经鼻灌注）在单次延长应激（SPS）前30分钟单次给药处理大鼠。HS014 TFA（100μg）显著降低了SPS应激源结束后30分钟血浆皮质酮的升高幅度，同时两种剂量均防止了应激诱导的基底内侧下丘脑中促肾上腺皮质激素释放激素（CRH）以及蓝斑中酪氨酸羟化酶（TH）和多巴胺-β-羟化酶（DBH）mRNA水平的短期升高[8]。
| Cell experiment [1]: | |
Cell lines | Epidermal melanocytes and Keratinocytes |
Preparation Method | Epidermal melanocytes and keratinocytes (phototype III) were seeded in six-well plates and pre-incubated in medium lacking supplemented tetradecanoylphorbol acetate for 48 hours. Before stimulation, the specific MC4-R antagonist HS014 TFA (10nM-200nM) was added to the appropriate wells. |
Reaction Conditions | 10nM-200nM; 30min. |
Applications | HS014 TFA significantly attenuated the induction of melanin formation in melanocytes stimulated by β-MSH or NDP-α-MSH over 72 hours. In both melanocytes and keratinocytes, HS014 TFA attenuated the cAMP response induced by β-MSH or NDP-α-MSH after 1 hour of stimulation. |
| Animal experiment [2]: | |
Animal models | Adult male Sprague-Dawley rats |
Preparation Method | Rats were implanted with a radiotelemetry transmitter for core body temperature (Tc) monitoring and a guide cannula in the right lateral ventricle for intracerebroventricular (icv) injection. On the experiment day, rats received an intraperitoneal (i.p.) injection of bacterial endotoxin lipopolysaccharide (LPS; 30µg/kg) to induce fever, followed 30 minutes later by the icv injection of HS014 TFA or vehicle (artificial cerebrospinal fluid, aCSF). Tc and motor activity were recorded continuously, and tail skin temperature (Tsk) was measured hourly. |
Dosage form | 1µg in 5µl; icv; single injection. |
Applications | HS014 TFA had no significant effect on the LPS-induced febrile increase in core body temperature (Tc) or the associated decrease in tail skin temperature (Tsk) in rats. HS014 TFA also had no significant effect on Tc, Tsk, or motor activity in afebrile (saline-treated) rats. However, the same dose of HS014 TFA completely blocked the antipyretic and anti-vasoconstrictive effects of a co-administered selective MC4R agonist (MRLOB-0001; 150ng; icv) during the first phase of fever. |
References: | |
| Cas No. | SDF | ||
| 分子式 | C73H95F3N20O19S2 | 分子量 | 1677.78 |
| 溶解度 | DMSO : 100 mg/mL (59.60 mM; Need ultrasonic) | 储存条件 | -20°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 596 μL | 2.9801 mL | 5.9603 mL |
| 5 mM | 119.2 μL | 596 μL | 1.1921 mL |
| 10 mM | 59.6 μL | 298 μL | 596 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet